Life Sciences

  • July 31, 2026

    J&J's $25M Talc Appeal Can Advance, Conn. Panel Rules

    A Connecticut appeals court has advanced Johnson & Johnson's challenge to a $25 million talc trial judgment, denying a Massachusetts real estate developer's attempt to dismiss the appeal based on what he argued was a late-filed brief.

  • July 31, 2026

    AI Drugmaker Investors Seek Final OK For $9.75M Fraud Deal

    A class of investors in the artificial intelligence-driven drugmaker BioXcel Therapeutics Inc. has moved for final approval of a $9.75 million settlement to resolve claims that the stock price plunged after the company's late disclosure of compliance problems with a clinical trial for an Alzheimer's drug, and class counsel is seeking around 25%.

  • July 31, 2026

    No Standing For NY 'Aid-In-Dying' Law Challenge, Judge Rules

    A New York federal judge tossed a challenge by disability rights organizations and individuals to a state law enacted this year allowing patients with terminal illnesses to seek a doctor's assistance in ending their lives, finding the group lacked standing.

  • July 31, 2026

    Just For Men Maker Says Insurers Must Cover Injury Deals

    The maker of Just For Men hair color products said in a new federal complaint that its excess liability insurers improperly refused to cover personal injury lawsuit settlements connected to allegations that products from the popular line permanently discolored users' faces, after millions in the company's primary policies were exhausted.

  • July 31, 2026

    Insulet Urges Full Fed. Circ. To Revive $59M Trade Secret Win

    Insulin product developer Insulet Corp. has asked the full Federal Circuit to hear its arguments for reinstating a jury's $59.4 million trade secret theft verdict against EOFlow Co. Ltd., saying a split panel decision overturning the award reached a timeliness issue that was not mentioned by either party.

  • July 30, 2026

    9th Circ. Reverses Hologenix CEO's Tortious Interference Loss

    A Ninth Circuit panel reversed a $2.5 million judgment Thursday against Hologenix CEO Seth Casden by finding a district court erred in ruling the executive is not immune from a tortious interference claim while also reversing a Lanham Act disgorgement award totaling nearly $3 million.

  • July 30, 2026

    NC, Green Groups Call EPA-Chemours PFAS Deal Too Lenient

    North Carolina state leaders and environmental organizations asked the federal government to walk back a proposed settlement with Chemours over so-called forever chemical pollution from three factories, saying the deal amounted to a slap on the wrist.

  • July 30, 2026

    Health Plans Ask 2nd Circ. To Revive Celgene Cancer Drug Row

    Health plans and pharmacies backed by Cigna are asking the Second Circuit to revive a proposed class action alleging Bristol-Myers Squibb Co. and its Celgene subsidiary fraudulently obtained patents, filed sham lawsuits and paid off generic-drug makers to maintain a monopoly on the blockbuster blood cancer drug Pomalyst.

  • July 30, 2026

    CBP Outlines Rates, Classifications For Pharma Tariffs

    U.S. pharmaceutical giants aren't expected to face various tariff rates up to 100% on certain imported patented drugs and ingredients beginning Friday, but all importers must begin to classify their goods that will eventually be subject to the duties, according to customs guidance published Thursday.

  • July 30, 2026

    Albertsons Can't Nix 14 Years Of Opioid Claims At Wash. Trial

    Albertsons and Safeway can't dodge 14 years' worth of claims in Washington state's lawsuit accusing the grocery stores' pharmacies of irresponsibly dispensing prescription opioids and fueling the state's overdose crisis, according to a Seattle judge's ruling Wednesday striking the companies' statute-of-limitations defense.

  • July 30, 2026

    Squires Erases PTAB Ax Of Dermatology IP Upheld At ITC

    U.S. Patent and Trademark Office Director John Squires has thrown out the Patent Trial and Appeal Board's finding that Biofrontera Inc. had shown that all the challenged claims of a Sun Pharmaceutical Industries Inc. patent on a photodynamic dermatology device are invalid as obvious.

  • July 30, 2026

    Curium, Sazerac And Stripe Pursue Megadeals, And More

    Reports of potential multibillion-dollar deals were plentiful this week, with U.S. alcohol producer Sazerac steadfast in its $15 billion pursuit of the maker of Jack Daniel's; Curium reportedly in advanced talks to acquire fellow radiopharmaceutical firm Lantheus Holdings Inc. for up to $8 billion; and Nvidia, Stripe and Devon Energy all linked to sizable strategic bets of their own.

  • July 30, 2026

    2nd Circ. Revives Decongestant 'Maximum Strength' Claims

    The Second Circuit on Thursday revived claims in multidistrict litigation alleging makers of oral decongestants misled consumers by labeling their products as "maximum strength," while finding the bulk of the remaining claims were preempted by federal regulation.

  • July 30, 2026

    Covidien Hid Mesh Risks, Bellwether Jury Told As Trial Ends

    Counsel for an Alabama man told a Massachusetts federal jury Thursday that Covidien LP failed to adequately warn doctors about the risks of complications from a hernia mesh implant, closing out the first bellwether trial among thousands of cases pending against the Medtronic unit.

  • July 30, 2026

    Squires Grants 6 Patent Petitions, Denies 4 In New Order

    U.S. Patent and Trademark Office Director John Squires has granted six requests for America Invents Act patent reviews and rejected four in his latest batch of decisions.

  • July 30, 2026

    J&J Pans Talc Claimant's 'Absurd' Bid To Nix $25M Appeal

    In a sharply worded memo, Johnson & Johnson told the Connecticut Appellate Court that it should deny a "nonsensical" dismissal motion from a real estate developer who won a $25 million asbestos-related cancer verdict, defending its appeal of the trial court outcome as timely.

  • July 30, 2026

    Pa. Paraquat, Gov. Shapiro's Neighbors: A Midyear Report

    Mass tort and antitrust cases advanced this year in Pennsylvania, where attorneys await Philadelphia's first paraquat trial and more developments in the class action against the Law School Admissions Council over test fees.

  • July 30, 2026

    2 Traders Admit Guilt In Stolen BigLaw Info Scheme

    Two men pled guilty Thursday in Massachusetts federal court to their roles in a sweeping scheme to trade on inside information stolen from huge corporate law firms about upcoming deals.

  • July 29, 2026

    Albertsons Pharmacy Work Was 'House Of Cards,' Judge Told

    Albertsons pharmacists in Washington state repeatedly warned supervisors that busy workloads and limited staffing were making it difficult to review prescriptions before filling them, a state judge in Seattle heard Monday, during a bench trial in Washington's case accusing Albertsons and its Safeway subsidiary of fueling the state's opioid crisis.

  • July 29, 2026

    2nd Circ. Backs Ex-Shkreli Atty's 401(k) Restitution Deal

    A New York trial judge erred in rejecting a retirement-fund garnishment deal that would have protected Martin Shkreli's convicted former lawyer from tax penalties, the Second Circuit ruled Wednesday.

  • July 29, 2026

    Novo Faces Narrowed Investor Suit Over Obesity Drug Claims

    A New Jersey federal judge narrowed a proposed securities class action against Novo Nordisk, preserving claims that it misled investors about the CagriSema obesity drug's tolerability and a flexible protocol used in a clinical trial.

  • July 29, 2026

    Depo-Provera MDL Gets New Lead Plaintiffs After Settlement

    The Florida federal judge overseeing the multidistrict litigation over a link between brain tumors and the hormonal contraceptive Depo-Provera on Wednesday approved three new pilot plaintiffs for the cases remaining after a global settlement that the judge called an "excellent outcome."

  • July 29, 2026

    Curaleaf Says Pot Suit Is Long On Length But Not Substance

    Cannabis giant Curaleaf Holdings Inc. on Tuesday slammed as "ill-conceived" a proposed class action by consumers who claim the company falsely marketed its products as medical treatments for mental health disorders and physical pain, saying none of the buyers are even medical cannabis patients.

  • July 29, 2026

    FTC Says Hims & Hers Shares Health Data, Misleads Users

    The Federal Trade Commission and regulators in California and Utah allege in a federal lawsuit filed Wednesday that Hims & Hers promises patient privacy while actually sharing consumers' sensitive health information with Meta Platforms and other third-party advertising platforms and that the telehealth provider has deceived users about its billing practices.

  • July 29, 2026

    Colo. Hospital Patients In Gender Care Suit Seek Class Cert.

    Transgender adolescents urged a Colorado state judge Wednesday to allow them to proceed as a certified class in their lawsuit seeking to have Children's Hospital Colorado resume providing gender-affirming care for them and other transgender youth patients, arguing the class is "objectively definable."

Expert Analysis

  • The Case For Using Final-Offer Damages Forms In IP Suits

    Author Photo

    Recent Federal Circuit decisions, such as Ollnova v. Ecobee, that scrutinize verdict forms in patent infringement disputes potentially render the final-offer damages selection procedure more attractive, though it should not be seen as a replacement for patent damages doctrine, says Brandon Theiss at Addy Hart.

  • Key Tips For Patenting Antibody-Drug Conjugate Inventions

    Author Photo

    Recent decisions highlight the significant challenges that can arise when patenting antibody-drug conjugates, which require strategic considerations for satisfying heightened written description and enablement requirements, says Xiaoban Xin at FisherBroyles.

  • $885M IBS Drug Verdict Tests Pay-For-Delay Limits

    Author Photo

    The outcome in the Amitiza Antitrust Litigation is significant because it is the first jury trial win for private antitrust plaintiffs in a suit challenging a patent settlement reverse payment since the U.S. Supreme Court adopted the rule-of-reason legal framework in 2013, offering a blueprint for pay-for-delay claims, say attorneys at Katten.

  • Series

    Power To The Paralegals: Burnout As A Structural Problem

    Author Photo

    Law firm leadership can best retain their paralegals not by encouraging self-care, but by seeking top-down structural solutions for the quiet proliferation of responsibilities and the vicarious exposure to client trauma that particularly drive burnout in this vital role, says Erika Sneeringer at Brockstedt Mandalas.

  • Class Actions At The Circuit Courts: June Lessons

    Author Photo

    In this month's review of class action appeals, Mitchell Engel at Shook Hardy discusses five recent rulings from cases involving allegations of internet data misuse, consumer fraud claims, immigration, insurance and First Amendment violation claims.

  • Takeaways From 1st Del. Ruling Applying Moelis Amendments

    Author Photo

    Delaware corporations should carefully review contractual arrangements and governance documents following the Court of Chancery's recent enforcement of a non-Delaware forum selection clause in a CEO's employment agreement under 2024 amendments to the state's General Corporation Law, say attorneys at Morgan Lewis.

  • Ill. Law Firm MSO Bill Clashes With Court Power, Ethics Rules

    Author Photo

    An Illinois bill prohibiting law firms from certain business arrangements with management service organizations, sent to the governor for signature last week, encroaches upon the courts' constitutional powers and goes beyond the Illinois Rules of Professional Conduct in regulating investment in law-related services, says Matthew O’Hara at Smith Gambrell.

  • The Future Of WDTX Patent Litigation After Judge Albright

    Author Photo

    With U.S. District Judge Christopher Wolfe set to take over much of Judge Alan Albright's patent infringement docket in the Western District of Texas later this year, attorneys should prepare for potential differences in Judge Wolfe's approach to the court's high volume of patent litigation, say attorneys at Sidley Austin.

  • Opinion

    State Courts Must Be Gatekeepers Of Expert Testimony

    Author Photo

    Based on my experience in the state judiciary, emulating federal courts' role as gatekeepers of expert witness testimony would help state court judges maintain the appearance of impartiality and assist juries, thus enhancing the overall confidence people have in their justice system, says Lorie Gildea at Greenberg Traurig.

  • 5 Key Factors Behind USPTO's Inter Partes Review Decisions

    Author Photo

    Though U.S. Patent and Trademark Office Director John Squires has drawn criticism for failing to explain his reasoning in inter partes review decisions, his recent precedential order in Magnolia v. Kurin provides five important insights into his decision-making process, says Christopher Loh at Venable.

  • Series

    Moshing Makes Me A Better Lawyer

    Author Photo

    Entering a mosh pit is much like entering the practice of law — it is difficult, you have to know both the written and unwritten rules, and conduct yourself according to the expectations of each community, says Christopher Deubert at Constangy Brooks.

  • High Court Ruling Casts Doubt On Status-Based Gun Bans

    Author Photo

    The U.S. Supreme Court’s recent ruling in U.S. v. Hemani demonstrates that the justices are increasingly skeptical of broad theories of categorical disarmament and clarifies that dangerousness cannot simply be presumed from one's status or membership in a statutory category, such as illegal drug use, says Lee Francis at Widener Law.

  • Why Highly Specialized Experts May Risk Exclusion At Trial

    Author Photo

    Expert witnesses with highly specific areas of focus may be vulnerable to exclusion in court, making it important for attorneys to check how potential witnesses' qualifications can be bolstered by their publications and other professional activities, say Evan Weisberg and Christopher Cunio at Hunton, and Kevin Cahill at FTI Consulting.

  • Generic Drugs Do Not Reach Patients Sooner In The EU

    Author Photo

    Although the U.S. and European Union take very different approaches to patents, regulatory exclusivities and drug pricing, data shows that the effective market life for brand-name drugs is essentially the same in both jurisdictions, says Margaret Kyle at Mines Paris.

  • A Midyear Look At Antiterrorism Act Jurisprudence And Policy

    Author Photo

    Plaintiffs have filed comparably fewer new actions under the Antiterrorism Act this year, though a handful of key decisions further defined the statute’s aiding-and-abetting standard and highlighted continuing risks for financial services companies, say attorneys at Skadden.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.